

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

XtalPi

晶泰科技

XtalPi Holdings Limited

晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF THE ACQUISITION OF LCC TECHNOLOGIES IN LIVERPOOL, UK

This announcement is made by XtalPi Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company is pleased to announce the completion of the acquisition (the “**Acquisition**”) of Liverpool ChiroChem (LCC) Technologies Limited (“**LCC Technologies**”), a UK company based in Runcorn, further enhancing the strength of the Group’s “AI+Robot” intelligent autonomous experimental platform in the field of chemical space exploration, and better serving local and international customers in the fields of new drug research and development, new material discovery and high-value chemicals.

INFORMATION ON LCC TECHNOLOGIES

LCC Technologies was founded in 2014 at the University of Liverpool, UK, and has long been committed to the design and synthesis technology research and development of novel molecules, especially new chiral molecules. The PACE (Parallel Automated Chiral Engine) technology platform developed by LCC Technologies combines AI software with automation technology, and can virtually screen target molecules in a chiral chemical library of billions of molecules, and efficiently complete the synthesis and put it into physical testing with the help of automated equipment. Users of this platform include multinational pharmaceutical companies and specialist biotech’s across the US, Europe and Asia.

At the same time, LCC Technologies’ long-term accumulation of chiral chemical molecular entity libraries and databases are world-leading in molecular quality and diversity, and can provide high-quality data support for artificial intelligence models in the exploration of chiral molecular chemical space.

In addition, LCC Technologies has accumulated complete technical solutions in the field of high-throughput and trace molecular library construction, which complements the large-scale molecular library construction technology of the Group's intelligent autonomous experimental platform.

REASONS FOR AND BENEFITS OF THE ACQUISITION

The Group primarily focuses on providing drug discovery and material science R&D solutions and services through integrated "AI + robotics" technology.

LCC Technologies' achievements in the field of chiral chemistry, when combined with the Group's innovative technologies such as AI and robots to serve pharmaceutical companies faster and better, will accelerate the healing of more people.

In addition, through the Acquisition, the Group's technical strength in the field of chemical space exploration continues to increase, and its ability to serve domestic and international customers will be further improved.

The Board (including the independent non-executive directors) is of the view that the Acquisition is in the interests of the Company and its shareholders as a whole.

As all applicable percentage ratios calculated under Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") are below 5%, the Acquisition does not constitute a notifiable transaction under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao

Chairman of the Board and Executive Director

Hong Kong, 12 June 2025

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.